Vardenafil dihydrochloride (0.03 mg/kg; i.v.) exhibits facilitator effects in rats with cavernous nerve injury[4].
Vardenafil dihydrochloride (0.17 mg/kg; i.v.; once daily; 7 d) protects liver against Con A–induced hepatitis, and decreases the expression of NF-B and iNOS in hepatic tissue[5].
Vardenafil dihydrochloride (10 mg/kg; p.o.; once daily; 25 weeks) prevents the reduction of tissue cGMP levels and the increase in 3-NT generation in ZDF hearts[6].
| Animal Model: | Male rat (9-week-old) underwent surgery for laparotomy or bilateral cavernous nerve (CN) crush injury[4] |
| Dosage: | 0.03 mg/kg |
| Administration: | Intravenous injection |
| Result: | Restored normal erectile responses with a combind administration of BAY 60-4552 (0.03, 0.3 mg/kg). |
| Animal Model: | Liver injury induced by Con A in male Swiss albino mice (20 ± 2 g)[5] |
| Dosage: | 0.17 mg/kg |
| Administration: | Intravenous injection; once daily, for 7 days; as a pretreatment |
| Result: | Reduced the levels of serum transaminases and alleviated Con A-induced hepatitis. |
| Animal Model: | Male 7-week-old Zucker diabetic fatty (ZDF) rats (preserved ejection fraction, HFpEF)[6] |
| Dosage: | 10 mg/kg |
| Administration: | Oral gavage; once daily, for 25 weeks |
| Result: | Improved myofilament function in diabetic rat hearts. |
